HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
- $ 3495
- April 2024
- 98 pages
ESCC, bile duct cancer (cholangiocarcinoma), RCC, non-small cell lung cancer (NSCLC), squamous cell carcinoma, esophageal cancer, small intestine cancer, adenocarcinoma of the gastroesophageal junction, colorectal cancer, cervical cancer, melanoma, Hodgkin lymphoma, head and neck cancer squamous cell carcinoma (HNSCC), gastric cancer, bladder cancer, small cell lung cancer (SCLC), solid tumor, endometrial cancer, gastroesophageal junction carcinomas, HCC, HER2- BC, Merkel cell carcinoma, metastatic transitional (urothelial) tract cancer, NMIBC, primary mediastinal B-cell lymphoma, TNBC